Divi’s Lab inks supply pact with global pharmaceutical entity

 The company expects meaningful revenue contribution from this long-term agreement
| Photo Credit:
AMIT DAVE

Divi’s Laboratories on Friday said it has inked a supply agreement with a global pharmaceuticals firm.

Under the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties, Divi’s Laboratories said in a regulatory filing.

The company expects meaningful revenue contribution from this long-term agreement, it added without disclosing the identity of the partner.

“The company is planning for capacity addition at its manufacturing facilities with an estimated investment between ₹650 crore and ₹700 crore, to be funded from internal accruals,” it said.

Shares of the company were trading 2.07 per cent down at ₹5,638.35 apiece on BSE.

Published on April 18, 2025